STERIS plc (STE)

Over the past six months, STERIS Plc's stock price has declined by 20.08%, reaching new 52-week lows in early May 2026. Key events impacting the stock price include the fiscal Q3 2026 earnings, which led to an almost 8% decline due to margin pressure from tariffs. The company also released its Q2 2026 and Q1 2026 earnings. STERIS is scheduled to host a conference call to discuss its fiscal 2026 fourth quarter and full year results on May 12, 2026.

Demand for STERIS Plc's products and services generally exhibits stability, benefiting from consistent healthcare procedure volumes. Approximately 80% of the company's revenue is generated from recurring products and services, contributing to stable free cash flow. While overall demand is stable, there can be some cyclicality in specific segments, such as bioprocessing. The company's diversified customer base helps to mitigate potential regional demand shocks.

STERIS Plc is an American-Irish medical equipment company specializing in infection prevention and procedural products and services, operating within the Healthcare sector and Medical Devices industry. It functions as a distributor of healthcare products with legal headquarters in Dublin, Ireland, and operational headquarters in Mentor, Ohio, U.S. STERIS's business is segmented into Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, with a divested Dental segment in fiscal 2025. The Healthcare segment provides comprehensive offerings for healthcare providers, the AST segment supports medical device and pharmaceutical manufacturers, and the Life Sciences segment offers products and services for biopharmaceutical and medical device research and manufacturing facilities.

STERIS supports customers worldwide through a network of manufacturing facilities, sales offices, service centers, and R&D sites across North America, Europe, Asia-Pacific, Latin America, and other international markets. Key operational locations include Tullamore, Ireland; Leicester, United Kingdom; and Plymouth, Minnesota, USA. The United States accounts for the largest portion of net sales at 73.4%, with Ireland contributing 2%, and other regions making up 24.6%.

STERIS Plc maintains a strong brand reputation as a leading global provider of infection prevention and other procedural products and services. The company emphasizes its mission to help customers create a healthier and safer world by providing innovative healthcare and life science products and services. STERIS is recognized for its commitment to sustainability and ethical business practices, requiring all associates to adhere to a Code of Business Conduct and prohibiting bribery and corruption.

The ownership of STERIS Plc is predominantly institutional, with institutional investors holding approximately 92.88% of shares as of April 2025. Individual investors hold about 4.88%, and insiders hold approximately 0.24%. Major institutional shareholders include Vanguard Group Inc., BlackRock Inc., State Street Corp, Massachusetts Financial Services Co, Morgan Stanley, Geode Capital Management, Llc, Orbis Allan Gray Ltd, Generation Investment Management Llp, Select Equity Group, L.P., and Wellington Management Group Llp.